P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
Bibliographic record
Abstract
Topic: 8. Chronic myeloid leukemia - Clinical Background: Ponatinib is the only pan-BCR::ABL1 inhibitory tyrosine kinase inhibitor (TKI) designed to potently inhibit native and all single resistance–mutation variants of BCR::ABL1, including T315I. Patients with T315I BCR::ABL1 mutations respond inadequately to earlier-generation BCR::ABL1 TKIs, leading to poor survival outcomes. OPTIC (Optimizing Ponatinib Treatment in CP-CML, NCT02467270) is a Phase 2 trial evaluating the efficacy and safety of ponatinib using a novel response-based dose-adjustment strategy in patients with chronic-phase chronic myeloid leukemia (CP-CML) whose disease is resistant to ≥2 TKIs or who harbor the T315I mutation. Aims: Here we present a post hoc analysis of the 3-year OPTIC trial patient responses by T315I mutation status. Methods: Patients with CP-CML resistant to ≥2 TKIs or with the BCR::ABL1 T315I mutation were randomized to ponatinib starting doses of 45, 30, or 15 mg once daily. In the 45-mg and 30-mg cohorts, doses were reduced to 15 mg with achievement of ≤1% BCR::ABL1IS. The primary endpoint was ≤1% BCR::ABL1IS at 12 months; secondary endpoints included molecular responses and safety outcomes. Progression-free survival (PFS) and overall survival (OS) probabilities by 36 months were estimated using the Kaplan-Meier methodology. Here we analyzed outcomes by baseline T315I mutation status. BCR::ABL1 mutations were assessed by Sanger sequencing. Results: Overall, 282 patients (99% resistant) received ponatinib (45 mg/30 mg/15 mg: n=94/94/94); 23.4% had the T315I mutation. In patients with no mutation, the T315I mutation, and mutation other than T315I, the highest percentage of patients achieving ≤1% BCR::ABL1IS by 36 months was in the 45-mg cohort: 60%, 64%, and 56%, respectively (Table). In patients with the T315I mutation, 32% (8/25) and 10% (2/20) in the 45-mg and 30-mg cohorts had their dose re-escalated after loss of response; of these patients, 75% and 50% re-achieved ≤1% BCR::ABLIS, respectively. In patients with no mutation, 6% (3/50) and 5% (3/58) in the 45-mg and 30-mg cohorts had their dose re-escalated after loss of response; of these patients, 67% and 100% re-achieved ≤1% BCR::ABLIS, respectively. In patients with a mutation other than T315I, 12.5% (2/16) in the 45-mg cohort had their dose re-escalated after loss of response and 50% (1/2) of these patients re-achieved ≤1% BCR::ABLIS; no patients in the 30-mg cohort lost response. Among patients with the T315I mutation, the 45-mg cohort had a higher 3-year PFS rate (75%) than the 30-mg (40%) or 15-mg (61%) cohorts; the 3-year OS rate was similar in the 45-mg (86%) and 15-mg (85%) cohorts (Table). Most-common Grade ≥3 treatment-emergent adverse events were thrombocytopenia (27%), neutropenia (18%), and anemia (8%). Incidences of Grade 3–4 arterial occlusive events (AOEs) in the 45-, 30-, and 15-mg cohorts were 6%, 6%, and 4%, respectively; there were no Grade 5 AOEs. Summary/Conclusion: This post hoc analysis from the 3-year update of the OPTIC trial demonstrated robust long-term efficacy of ponatinib and manageable safety across mutation subgroups. A ponatinib starting dose of 45 mg with reduction to 15 mg upon achievement of ≤1% BCR::ABL1IS provided the optimal benefit:risk ratio regardless of mutation status, which is consistent with the results from the primary analysis.Keywords: Chronic myeloid leukemia
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".